Fortis Capital Management LLC Invests $5.90 Million in Boston Scientific Corporation $BSX

Fortis Capital Management LLC acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,382 shares of the medical equipment provider’s stock, valued at approximately $5,895,000.

A number of other large investors have also added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of Boston Scientific during the 2nd quarter valued at $2,089,937,000. Edgewood Management LLC bought a new stake in shares of Boston Scientific in the second quarter worth $746,655,000. Parnassus Investments LLC increased its position in Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after acquiring an additional 6,868,459 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Boston Scientific by 14,391.8% in the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after acquiring an additional 2,899,653 shares during the period. Finally, Jennison Associates LLC boosted its position in Boston Scientific by 133.5% in the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after purchasing an additional 2,823,744 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BSX. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research report on Monday, February 2nd. JPMorgan Chase & Co. reduced their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. The Goldman Sachs Group set a $99.00 price target on shares of Boston Scientific in a research report on Thursday, February 5th. Finally, UBS Group cut their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $108.36.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Down 1.6%

BSX opened at $74.54 on Monday. The stock has a market cap of $110.61 billion, a price-to-earnings ratio of 38.42, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm’s fifty day moving average is $89.23 and its 200 day moving average is $96.53. Boston Scientific Corporation has a fifty-two week low of $72.69 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the firm earned $0.70 earnings per share. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.